Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Olodanrigan - Novartis

Drug Profile

Olodanrigan - Novartis

Alternative Names: EMA-401

Latest Information Update: 15 May 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Spinifex Pharmaceuticals
  • Developer Novartis
  • Class Analgesics; Small molecules; Tetrahydroisoquinolines
  • Mechanism of Action Angiotensin type 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Diabetic neuropathies; Neuropathic pain; Postherpetic neuralgia

Most Recent Events

  • 10 Apr 2019 Novartis terminates the phase-II EMPHENE trial in Post-herpetic Neuralgia (Treatment-experienced) in Australia, Austrial, Belgium, Canada, Czech Republic, Denmark, France, Germany, Hungary, Italy, Japan, South Korea, Norway, Poland, Portugal, Slovakia, Taiwan, United Kingdom, Spain (PO) (NCT03094195)
  • 28 Mar 2018 No recent reports of development identified for phase-I development in Neuropathic-pain(In volunteers) in Australia (PO, Tablet)
  • 28 Mar 2018 No recent reports of development identified for phase-I development in Postherpetic-neuralgia(In volunteers) in Australia (PO, Tablet)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top